I
Ghosh A, Tyson T, George S, Hildebrandt EN, Steiner JA, Madaj Z, Schulz E, Machiela E, McDonald WG, Escobar Galvis ML, Kordower JH, Van Raamsdonk JM, Colca JR, Brundin P
Science Translational Medicine | 07 Dec 2016 : 368ra174
Mitochondrial pyruvate carrier regulates autophagy, inflammation, and neurodegeneration in experimental models of Parkinson’s disease
Colca JR
Atlas of Science [online summary of Expert Opin Drug Discovery 2015 Oct 19:1-12, for general interest readers]
A new understanding of the mechanism of action of insulin sensitizing drugs provides insight into treating metabolic disease
Colca JR
Expert Opin Drug Discov 2015, 10(12):1259-70
The TZD insulin sensitizer clue provides a new route into diabetes drug discovery
McCommis KS, Chen Z, Fu X, McDonald WG, Colca JR, Kletzien RF, Burgess SC, Finck B
Cell Metab. 2015 Oct 6;22(4):682-94. doi: 10.1016/j.cmet.2015.07.028. Epub 2015 Sep 3.
Loss of mitochondrial pyruvate carrier 2 in the liver leads to defects in gluconeogenesis and compensation via pyruvate-alanine cycling
Colca JR
Expert Opin Investig Drugs. 2015;24(9):1241-5. doi: 10.1517/13543784.2015.1058777. Epub 2015 Jun 17
Discontinued drug therapies to treat diabetes in 2014
Shah RC, Matthews DC, Andrews RD, Capuano AW, Fleischman DA, VanderLugt JT, Colca JR
Current Alzheimer Research, 2014, 11, 564-573
An Evaluation of MSDC-0160, a Prototype mTOT Modulating Insulin Sensitizer, in Patients with Mild Alzheimer’s Disease
Colca JR, McDonald, WG, Kletzien RF
Diabetes Obes Metab. 2014 Apr 29. doi: 10.1111/dom.12308. [Epub ahead of print]
Mitochondrial Target of Thiazolidinediones
Colca JR, Tanis SP, McDonald WG & Kletzien RF
Expert Opin Investig Drugs. Posted online on September 27, 2013 [Epub ahead of print]: Pages 1-7
Insulin sensitizers in 2013: new insights for the development of novel therapeutic agents to treat metabolic diseases
Colca JR
Expert Opin Investig Drugs. 2013 Aug 21. [Epub ahead of print]
Discontinued drugs in 2012: endocrine and metabolic
Colca JR, McDonald WG, Cavey GS, Cole SL, Holewa DD, Brightwell-Conrad AS, Wolfe CL, Wheeler JS, Coulter KR, Kilkuskie PM, Gracheva E, Korshunova Y, Trusgnich M, Karr R, Wiley SE, Divakaruni AS, Murphy AN, Vigueira PA, Finck BN, Kletzien RK
PLOS ONE 8(5): e61551
Identification of a Mitochondrial Target of Thiazolidinedione Insulin Sensitizers (mTOT) – relationship to newly identified mitochondrial pyruvate carrier proteins
Rohatgi N, Aly H, Marshall CA, McDonald WG, Kletzien RF, Colca JR, and McDaniel ML
PLoS ONE 8(5): e62012
Novel Insulin Sensitizer Modulates Nutrient Sensing Pathways and Maintains b-Cell Phenotype in Human Islets
Colca JR , VanderLugt JT, Adams WJ, Shashlo A, McDonald WG, Liang J , Zhou R and Orloff DG
Clinical Pharmacology & Therapeutics advance online publication 6 March 2013
Clinical Proof-of-Concept Study with MSDC-0160, a Prototype mTOT-Modulating Insulin Sensitizer
Chen Z, Vigueira PA, Chambers KT, Hall AM, Mitra MS, Qi N, McDonald WG, Colca JR, Kletzien RF, Finck BN
J Biol Chem. 2012 May 23. [Epub ahead of print]
Insulin Resistance and Metabolic Derangements in Obese Mice are Ameliorated by a Novel Peroxisome Proliferator-Activated Receptor γ-sparing Thiazolidinedione
Colca JR, Feinstein, DL
Adv Pharmacol. 2012;64:155-76
Altering mitochondrial dysfunction as an approach to treating Alzheimer’s disease
Colca JR, Kletzien RF
Adv Pharmacol. 2009;57:237-51. Epub 2009 Nov 27.
Current and emerging strategies for treating dyslipidemia and macrovascular disease.
Bolten CW, Blanner PM, McDonald WG, Staten NR, Mazzarella RA, Arhancet GB, Meier MF, Weiss DJ, Sullivan PM, Hromockyj AE, Kletzien RF, Colca JR.
Gene Regul Syst Bio. 2007 Sep 17;1:73-82.
Insulin sensitizing pharmacology of thiazolidinediones correlates with mitochondrial gene expression rather than activation of PPAR gamma.
Colca JR.
Biochem Pharmacol. 2006 Jul 14;72(2):125-31. Epub 2006 Feb 10.
Insulin sensitizers may prevent metabolic inflammation.
Colca JR, Kletzien RF
Expert Opin Investig Drugs. 2006 Mar;15(3):205-10.
What has prevented the expansion of insulin sensitisers?
Copyright © 2022 Metabolic Solutions Development Company - All Rights Reserved.